Integrum has carried out a directed new issue of 961,539 series B shares, raising proceeds of approximately SEK 50 million | Placera
Summary
The Board of Directors of Integrum has, in accordance with the issue authorization granted by the annual general meeting on 27 September 2023, and as indicated in the press release by the Company earlier today, resolved on a directed issue of 961,539 new series B shares at a subscription price of SEK 52 per share, consequently raising gross proceeds of approximately SEK 50 million. The subscription price in the Directed Issue has been determined through an accelerated book building procedure, which is why the assessment of the Board of Directors that the subscription price will accurately reflect the current market conditions and demand.A number of Swedish and international institutional investors participated in the Directed Issue, including Adrigo Asset Management, Nolsterby Invest AB and Rhenman & Partners Asset Management AB.Integrum intends to use the net proceeds from the Directed Issue for investments into commercial resources and distribution, as well as for clinical affairs and continued product portfolio expansion. This includes: Intensification of commercial efforts within the US market, to advance targeting of relevant trauma centers, CPOs and surgeons. Expansion of product portfolio and addressable indications in the US, including investments in regulatory affairs for the submission of the PMA application for transhumeral (above-elbow) and transtibial (below-knee) amputations, as well as strengthen and accelerate research and product development capabilities for next-generation products.The Directed Issue entails a dilution of 5.0 percent of the total number of outstanding shares and 3.8 percent of the votes in Integrum. Rickard Br\xe5nemark has expressed his continued long-term commitment to the Company as its CEO and founder and as a majority shareholder.